New drug trial aims to stop dangerous bleeding in rare blood disorder
Disease control
Ongoing
This early-stage clinical trial is testing a new drug called HMB-001 in adults with Glanzmann thrombasthenia, a rare inherited bleeding disorder. The main goals are to find a safe dose and see if regular injections can prevent or reduce the number and severity of bleeding episode…
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Apr 02, 2026 08:42 UTC